Harness tissue regeneration to treat ulcers, intractable wounds
Allander Biotechnologies, LLC is a seed-stage company developing fusion protein biologics to treat inflammatory diseases and disorders with unmet medical needs including oral mucositis (extensive oral ulceration), radio-dermatitis, and chronic wounds. The technology is based on seminal research by the Founder, Dr. Xiao-Jing Wang, into the role of Smad7 on inflammation-associated tissue damage and defects in tissue regeneration. Our biologic drugs have been validated for topical and local administration in multiple animal models. Allander has a strong intellectual property portfolio exclusively licensed from the University of Colorado, and is looking for partners or additional investment to develop the biologic for licensing or acquisition.